

A Review and Clinical Perspective of the Impact of Osteoporosis on the Spine

Geriatric Orthopaedic Surgery
& Rehabilitation
Volume 10: 1-8
© The Author(s) 2019
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/2151459319861591
journals.sagepub.com/home/gos



Bayard C. Carlson, MD¹ , William A. Robinson, MD¹,
Nathan R. Wanderman, MD¹, Arjun S. Sebastian, MD¹,
Ahmad Nassr, MD¹, Brett A. Freedman, MD¹ ,
and Paul A. Anderson, MD¹

Abstract

Introduction: Osteopenia and osteoporosis are common conditions in the United States. The health consequences of low bone density can be dire, from poor surgical outcomes to increased mortality rates following a fracture. **Significance:** This article highlights the impact low bone density has on spine health in terms of vertebral fragility fractures and its adverse effects on elective spine surgery. It also reviews the clinical importance of bone health assessment and optimization. **Results:** Vertebral fractures are the most common fragility fractures with significant consequences related to patient morbidity and mortality. Additionally, a vertebral fracture is the best predictor of a subsequent fracture. These fractures constitute sentinel events in osteoporosis that require further evaluation and treatment of the patient's underlying bone disease. In addition to fractures, osteopenia and osteoporosis have deleterious effects on elective spine surgery from screw pullout to fusion rates. Adequate evaluation and treatment of a patient's underlying bone disease in these situations have been shown to improve patient outcomes. **Conclusion:** With an increased understanding of the prevalence of low bone mass and its consequences as well an understanding of how to identify these patients and appropriately intervene, spine surgeons can effectively decrease the rates of adverse health outcomes related to low bone mass.

Keywords

geriatric medicine, geriatric trauma, geriatric nursing, nonoperative spine, physical therapy

Submitted August 07, 2018. Revised June 03, 2019. Accepted June 05, 2019.

Introduction

Osteopenia and osteoporosis (low bone density) are common conditions in the United States that are increasing in prevalence as the population ages. As of 2010, there were 10.3 million Americans over the age of 50 years with osteoporosis and there were 43.4 million Americans with low bone mass (ie, osteopenia).¹ Over the next 20 years, these numbers are expected to increase by 32%.^{1,2} As the population continues to age, so too will the burden of diminished bone quality and its clinical sequelae. As the vertebral column represents the most common anatomic site of osteoporosis-related fractures, spine surgeons are uniquely positioned to help with the detection, evaluation, and management of low bone density.³⁻⁷ Moreover, diminished bone quality plays a large role in the ultimate success of elective spine surgery.³ The purpose of this review article is 3-fold: first, we will review the impact low bone density has on the spine; second, we will review the negative consequences of low bone density on clinical outcomes following elective spine

surgery; third, we will review the clinical importance of bone density assessment and optimization. Our intent is to provide a concise summary of the literature regarding the impact of low bone density and the importance of bone health optimization in patients with spinal disease.

Methods

A review of the literature pertaining to osteopenia and osteoporosis and its relation to vertebral fractures and elective spine surgery was performed. Using PubMed, a combination of the search terms “osteoporosis,” “osteopenia,” “fragility

¹ Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA

Corresponding Author:

Brett A. Freedman, Department of Orthopedic Surgery, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA.

Email: freedman.brett@mayo.edu



Table 1. Literature Summary by Topic.

Fragility fracture and osteoporosis epidemiology References: ^{1,2,7-21}
Treatment strategies and treatment deficiencies following fragility fracture References: ²²⁻³⁶
Bone health and elective spine surgery outcomes References: ^{3,5,6,36-59}
Osteoporosis treatment and elective spine surgery outcomes References: ^{8,39,60-68}

Table 2. Indications for Bone Mineral Density Testing.⁸

1. All women \geq 65 years old
2. All postmenopausal women:
 - a. With a history of fracture(s) without major trauma
 - b. With osteopenia identified radiographically
 - c. Starting or taking long-term systemic glucocorticoid therapy (\geq 3 months)
3. Other peri- or postmenopausal women with risk factors for osteoporosis if willing to consider pharmacologic interventions:
 - a. Low body weight (<127 lb or body mass index <20 kg/m²)
 - b. Long-term systemic glucocorticoid therapy (\geq 3 months)
 - c. Family history of osteoporotic fracture
 - d. Early menopause (<40 years old)
 - e. Current smoking
 - f. Excessive alcohol consumption
4. Secondary osteoporosis

fracture,” “vertebral fragility fracture,” “osteoporosis management,” “spine fusion,” “complications,” and “elective spine surgery” were used to find the literature relevant to the topic under review. All titles and then abstracts were reviewed for relevance. Those deemed relevant and in scope to the stated purposes of this review were read in full text, and information supportive to this review article was abstracted. The articles included in the review are listed by topic in Table 1.

Basic Concepts in Osteoporosis

Bone density is a critical component of a patient’s bone health status. The most common method for diagnosing osteoporosis is densitometric assessment. To classify a patient’s bone density, dual energy X-ray absorptiometry (DXA) is used to determine an individual’s bone mineral density (BMD). The subject’s BMD is then compared to a reference standard, specifically the BMD of a 20- to 30-year-old adult race-matched normative cohort to generate a T score.⁶⁹ The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) guidelines for obtaining screening DXA are presented in Table 2.⁸

The World Health Organization (WHO) uses T scores to classify an individual’s bone health status. Low bone mass, also called osteopenia, is defined as a DXA T score between -1 and -2.5 . Osteoporosis is defined as a DXA T score < -2.5 .⁸ Dual energy X-ray absorptiometry measures BMD

Table 3. 2016 AACE Diagnosis of Osteoporosis in Postmenopausal Women.⁴

1. T-Score of -2.5 or below in the lumbar spine, femoral neck, total, and/or 33% (one-third) radius
2. Low-trauma spine or hip fracture (*regardless of BMD*)
3. Osteopenia or low bone mass (T-score between -1 and -2.5) with a fragility fracture of proximal humerus, pelvis, or possibly distal forearm
4. Low bone mass or osteopenia and high FRAX fracture probability based on country-specific thresholds

Abbreviations: AACE, American Association of Clinical Endocrinologist; BMD, bone mineral density.

at multiple locations and the lowest T score is used to classify an individual’s bone density status. While the WHO definition of BMD provides a useful benchmark for understanding a patient’s overall bone health, these criteria do not adequately determine the risk of fragility fracture.⁹ In fact, the majority of patients who sustain fragility fractures do not have osteoporosis based on the WHO criteria.⁸ In light of this deficiency, the AACE and the ACE developed clinical practice guidelines in 2016 that added clinical criteria to the definition of osteoporosis (Table 3).⁸ These standards recognize that the presence of a spine or hip fragility fracture, regardless of BMD, confirms the diagnosis of osteoporosis. Further, AACE/ACE clinical practice guidelines indicate that patients with osteopenia (T score -1 to -2.5) and a fragility fracture of the pelvis, wrist, or shoulder should be diagnosed with osteoporosis.⁸

Vertebral Fragility Fracture

Fragility fracture is the sentinel event in osteoporosis and the most morbid effect of low bone mass on the spine. Fragility fractures represent a major burden to the health-care system in the United States with over 2.1 million patients sustaining a fragility fracture at any anatomic location in 2011, a number greater than the occurrence of breast cancer, myocardial infarction, and stroke combined.^{4,10} In the United States, there were over 4.9 million hospitalizations as a result of fragility fractures with an estimated cost of \$17 billion per year between 2000 and 2012.⁴ Over 260 000 patients are hospitalized annually for vertebral fracture; however, this is only the tip of the iceberg as 2 in 3 vertebral fragility fractures are clinically silent and a majority of these fractures are treated in an outpatient setting.^{7,11,12} Vertebral fractures are the most common type of fragility fracture and the incidence of these fractures increases with age and also varies by gender, with females having a 4 to 5 times higher risk of fracture than men.¹³

While many view vertebral fragility fractures as benign, requiring mostly comfort care, they are often associated with significant pain and disability.^{14,22,23,24,25} Tosteson et al assessed long-term, health-related quality-of-life outcomes at 5 years in 215 patients who presented with hip and vertebral fractures compared to 200 control patients.¹⁴ They found that 25% of patients with vertebral fractures reported limitations in

activities of daily living and over two-thirds of patients reported limitations if they had a combined hip and spine fracture.¹⁴ Chen et al, in a study assessing options for management of vertebral compression fractures, reported an average baseline pain of 7.8 on the visual analog scale which significantly improved following conservative treatment, but still remained 3.4 at 6 months.²² While the pain improved, the persistence highlights the long-term significance of this injury.

Patients with symptomatic vertebral fragility fractures are also at an increased risk of mortality, with studies showing a 2 to 8 times increased risk of age-matched mortality following a symptomatic vertebral fracture.¹³ Patients have the highest risk of mortality within the first 6 months following a vertebral fracture.¹³ Lau et al assessed Medicare claims and found that the mortality following vertebral fracture was 46.1%, 68.1%, and 89.5% at 3, 5, and 8 years, respectively.¹⁵ They then adjusted for comorbidities and found that vertebral fracture alone was associated with a hazard ratio of 1.83 for mortality.¹⁵ Surprisingly, mortality following a vertebral fragility fracture approaches that following a hip fracture which has been shown to be 28.3% at 1 year.¹⁶ Further, surviving patients are significantly more likely to require long-term nursing care and to drop to a lower income status following the hip fracture.¹⁶ Chen et al identified similar losses in independence after vertebral fracture.²²

Another cost of vertebral fracture is related to emotional changes. Svensson et al performed a structured questionnaire on octogenarians who had a prior vertebral fragility fracture. They found that fear and anxiety was a dominant complaint. Patients experienced fear of recurrent pain, struggled to understand their deceiving body, and experienced loss of independence as well as fear of an uncertain future.¹⁷ Thus, pain and deformity is not the only clinically significant impact of vertebral fragility fracture.

Fragility fractures are the strongest predictor of subsequent fragility fractures. Hodsmann et al reported that at 5 and 10 years following a vertebral fracture, secondary fractures had occurred in 16.3% and 25.7% of patients, respectively.¹⁸ A meta-analysis performed by Anderson et al found that 18% of patients with nonoperatively treated vertebral fractures sustained secondary fractures within 12 months.²⁶ Another meta-analysis showed that a previous fracture history was associated with a significantly increased risk of any fracture when compared to individuals without prior fracture.¹⁹ Further, Lindsay demonstrated that patients with more than one vertebral fracture had double the risk of secondary fracture.²⁰

Given the morbidity and mortality associated with fragility fractures as well as the significantly increased risk of subsequent fracture, a fragility fracture must be considered a sentinel event by all providers attending to the fracture. It should prompt a clinical diagnosis of osteoporosis and a process of management (typically led by the primary care provider or a bone health specialist, such as an endocrinologist, rheumatologist, geriatrician, or a fracture liaison service) that includes evaluating bone density and bone health. In addition to subsequent medical treatment, fall prevention and counseling

regarding calcium and vitamin D usage, regular exercise, and smoking cessation play a critical role in preventing subsequent fractures. However, over the last decade, fewer than 20% to 30% of patients have received adequate bone health evaluation, follow-up, and treatment after sustaining a fragility fracture.²⁷⁻²⁹ Bawa et al assessed osteoporosis care after fragility fracture in over 31 000 patients and found that only 10.6% of patients were treated with anti-osteoporotic medications following the index fracture.³⁰ In the 10.6% of patients that did receive anti-osteoporotic therapy, there was a 40.6% reduction in subsequent fractures.³⁰ Hawley et al assessed the results following governmental recommendations that hip fracture patients were prescribed bisphosphonates for secondary fracture prevention in Great Britain and found that 3 years after the initiation of the intervention, there was a 22% reduction in subsequent hip fracture and a 14% reduction in major osteoporotic fracture (including vertebral fractures).³¹

The recommendations for assessing and managing osteoporosis are not vague or difficult to find; compliant implementation of these measures results in >40% to 80% reduction in subsequent fragility fracture of the spine.³⁰ Thus, the missing link is not the need of a better means for diagnosing or treating this disease, rather it is simply the need to initiate the process.²¹ While spine specialists may not have the extended patient contact required to manage the prescription and surveillance of anti-osteoporotic therapy, we certainly know the impact that osteoporosis has on spine health. It should be the aim of all spine specialists consulted for vertebral fragility fracture to not only treat the fracture, but also to have an informative bone health-care discussion with the patient. This conversation, at a minimum, should include informing the patient that they have osteoporosis, recommending DXA scanning, and instructing the patient to follow-up with their primary care provider or with a bone health specialist to initiate anti-osteoporotic therapy. The *Own the Bone* (OTB) initiative described below provides a roadmap for a successful strategy to prevent subsequent fragility fractures.

Given the impact of fragility fractures, in 2004, the United States Surgeon General issued a report stating that bone health was among the most important health issues facing Americans. In response to this report, the American Orthopaedic Association (AOA) created the OTB Program.³² The program focuses its efforts on the prevention of secondary fractures.^{33,34}

As of June 2016, there were 147 enrolling institutions.³⁵ Of the 33 158 enrolled patients, 27.8% of patients presented with an axial fracture involving the spine or pelvis.³⁵ It should be noted that over 99% of the participating OTB sites enroll patients in the in-patient setting, which skews the proportion of fracture types seen. A vertebral compression fracture is the most common fragility fracture occurring in the general population but a majority are clinically silent or managed nonoperatively.²⁸ Roughly 36% of the enrolled patients had a previous fracture after the age of 50.³⁵

Dirschl and Rustom report that within the OTB program, 72.8% of patients had anti-osteoporosis treatment recommended and in this same cohort, 12.1% of patients were started

on anti-osteoporosis treatment. Roughly, 60% of the patients who did not receive treatment had treatment planned or were referred to their primary care provider with the intent of anti-osteoporosis treatment initiation.³⁵ Ultimately, the *AOA OTB* initiative is significantly improving anti-osteoporosis treatment in patients with fragility fractures. It, like fracture liaison programs across the globe, is making a difference by stressing the connection between low-energy fracture and osteoporosis.

Bone Fragility and Its Impact on Elective Spine Surgery

Many aspects of bone health have been shown to have an impact on spine surgery. For instance, vitamin D deficiency has been shown to be a prevalent issue that can adversely impact elective spine surgery.^{6,37,38} Ravindra et al found that 30.0% of patients undergoing elective spine fusion surgery had vitamin D deficiency; Stoker et al similarly found that 27.0% of patients undergoing spine fusion surgery had vitamin D deficiency.^{39,40} Subsequent studies have shown that vitamin D deficiency has a negative impact on spine fusion outcomes. Ravindra et al showed that vitamin D deficiency was an independent predictor of nonunion and that the time to fusion in patients with vitamin D deficiency was significantly longer.³⁸ A literature review performed by Kerezoudis et al found that patients presenting with vitamin D deficiency achieved lower fusion rates and had higher rates of persistent low back pain following spinal fusion.⁶ Kim found that functional outcome as measured by Oswestry Disability Index inversely correlated with baseline 25(OH) Vit D after spine surgery.³⁷ Thus, in order to maximize patient outcomes following elective spine surgery, it is important to fully investigate a patient's bone health, which includes DXA and laboratory assessment.

In addition to vitamin D deficiency, low bone density is associated with poor outcomes in spine surgery. Investigations have shown an association between low BMD and poor pedicle screw purchase, demonstrating that patients with osteoporosis are at increased risk of screw loosening, hardware failure, and interbody cage subsidence.^{5,36,41-45,46} The diminished bone density of cancellous bone and the associated increase in bone porosity in patients with osteopenia or osteoporosis contributes to implant failure by changing the vertebrae's ability to load share.⁴⁷ In a synthetic bone model, Varghese et al assessed pedicle screw pullout strength at different bone densities, finding significantly reduced pullout strength in the severely osteoporotic model.⁴⁸ Similarly, Halvorson et al found that decreased BMD was significantly correlated with pedicle screw axial pullout with pullout force averaging 206 ± 159 N in osteoporotic spines compared to 1540 ± 361 N in normal spines.⁴⁹ Clinically, studies by Sakai et al and Bredow et al have shown that low Hounsfield Units on computed tomography scans, a marker of low BMD, are predictive of pedicle screw loosening.^{43,44} Bjerke et al compared osteoporotic, osteopenic, and normal patients undergoing thoracolumbar fusion.³ They found that "osteoporosis-related complications" (such as proximal

junctional fracture or kyphosis and screw pullout) occurred in 50% of osteoporotic, 34% of osteopenic, and in 23% of patients with normal bone.³ Bernstein et al also found that, when compared to patients without rheumatoid arthritis, patients with rheumatoid arthritis had a significantly higher implant-related complication rate; osteoporosis was significantly more prevalent in this cohort of patients.⁴⁵ Additionally, Formby et al and Tempel et al both report that low BMD is associated with significantly increased cage or graft subsidence in patients undergoing transforaminal lumbar interbody fusions or lateral lumbar interbody fusions, respectively.^{36,46}

Nonunion is another complication seen more commonly in patients with osteoporosis.^{3,50,51} In the study by Bjerke et al, nonunion occurred in 46% of osteoporotic patients compared to 19% of patients with normal bone.³ Cho et al found that patients with osteoporosis undergoing a one-level posterior lumbar interbody fusion had a significantly higher rate of screw loosening which was associated with a significantly lower fusion rate.⁵⁰ DeWald et al, in a case series of patients over the age of 65 years undergoing spinal fusion involving a minimum of 5 levels, found a pseudarthrosis prevalence of 11%.⁵¹

Patients with osteoporosis are also at increased risk of proximal junctional failure following spinal fusion surgery.³ Yagi et al investigated risk factors for proximal junctional kyphosis (PJK) following long instrumented spinal fusion and found that patients who developed PJK were significantly more likely to have low bone density.⁵² Uei et al found that low bone density was significantly associated with increased rates of revision surgery for PJK and postoperative vertebral fractures.⁵³ O'Leary et al similarly found that decreased bone density was a risk factor for fractures at the most proximal end of long pedicle screw constructs.⁵⁴

The most proximal end of a fusion construct is not the only area at risk in patients with low bone density. Kwon et al describe a case series of 13 patients presenting with caudal junctional failure and found that 79% of these patients had low bone density.⁵⁵ Furthermore, Meredith et al found that osteoporosis is a significant risk factor for sacral fractures following multilevel spinal arthrodesis.⁵⁶ Papadopoulos et al similarly found that osteoporosis places patients at increased risk of sacral fracture following thoracolumbar fusion to the sacrum.⁵⁷

Finally, rates of revision surgery are higher in patients with low BMD with studies by Bjerke et al, Sheu et al, and Puvanarajah et al all demonstrating higher revision rates following spinal fusion surgery in patients with low BMD.^{3,58,59} These studies illustrate the high prevalence of poor bone health in spine patients and that variations from normal bone density (ie, low bone mass or osteoporosis) result in a significant increase in bone fragility-related complications and failure of fusion following spinal surgery.

Bone Health Assessment Prior to Elective Spine Surgery

Given the potential influence of bone health status on the risk of future fragility fracture and on the outcomes of elective spine

Table 4. Preoperative Vitamin D^a Supplementation.

1. All fusion patients have vitamin D levels checked preoperatively
2. Vitamin D levels between 30 and 60 ng/mL are considered normal
Any fusion patient with a vitamin D below 30 ng/mL is supplemented for 1 year as follows:
 - If more than 4 weeks before surgery:
 - Vitamin D level of 25 to 30 ng/mL then recommend cholecalciferol 1000 IU daily
 - Vitamin D level of 15 to 24 ng/mL then recommend cholecalciferol 2000 IU daily
 - If less than 4 weeks before surgery:
 - Vitamin D level of 25 to 30 ng/mL then recommend cholecalciferol 50 000 IU daily × 4 days followed by cholecalciferol 1000 IU daily
 - Vitamin D level of 15 to 24 ng/mL then recommend cholecalciferol 50 000 IU daily × 7 days followed by Cholecalciferol 2000 IU daily
 - If Vitamin D level is less than 15 ng/mL consider consulting endocrinology

^aVitamin D = total 25-hydroxyvitamin D.

surgery, the assessment of bone health is important. This assessment is performed by identifying risk factors of low bone mass. Current guidelines-recommended bone density screening are shown in Table 2. Diabetes is increasingly identified as a risk factor for fracture despite maintenance of normal BMD and may be considered an independent risk factor when considering bone density assessment. In addition, in all patients over the age of 50 years scheduled for an elective adult spinal deformity surgery or a long segment fusion (ie, >3 levels), a DXA scan may be appropriate as a routine preoperative assessment. Furthermore, a DXA scan should be obtained for all patients meeting the Table 2 guidelines, if one has not been obtained in the last 2 years.

If a patient is identified as having a low bone mass by DXA or if the patient has sustained a fragility fracture, the patient can be referred to a bone health specialist. All spine patients should be encouraged to consume the recommended daily allowances of vitamin D (800-1000 IU/d) and calcium (1200 mg/d).^{9,60} Low vitamin D levels lead to increased bone resorption and turnover, which in turn can predispose patients to osteoporosis.^{39,61,62} Ensuring adequate daily intake and/or supplementation when deficiencies are noted can mitigate these negative effects. An example of a strategy for preoperative vitamin D optimization based on expert opinion at the Mayo Clinic is shown in Table 4.

In patients considering elective spine surgery who have severe low bone mass (T score < -2.0; especially with a history of prior fragility fracture) or osteoporosis, surgeons should consider delaying surgery in order to initiate anabolic therapy (ie, teriparatide or abaloparatide) to optimize the patient's bone health. To be impactful, these medications should be started a minimum of 4 to 6 weeks prior to spine surgery and continued for up to 2 years.⁶³ It can take months for DXA scan values to change, but even prior to that, insertional torques for pedicle

screws can increase; likewise, perioperative administration of these agents is associated with increased fusion rates.⁶⁴

The ultimate goal of bone health optimization prior to elective spine surgery is to limit osteoporosis-related complications.¹⁴ The recognition of low bone mass and its subsequent treatment with an anabolic agent, such as teriparatide or abaloparatide, which stimulates osteoblastic activity, has been shown to enhance fusion rates while also helping to increase overall BMD.^{65,66} While some studies in animals have shown that bisphosphonates, which inhibit osteoclasts and catabolic bone metabolism, may limit fusion, the highest level of clinical information to date demonstrates that continuation of these agents in the perioperative period leads to higher fusion rates.^{67,68}

Conclusions

The health consequences of low bone mass can be dire, from poor surgical outcomes to increased mortality rates following a fracture. Spine surgeons are uniquely positioned to identify patients with low bone mass given its impact on all facets of their practice. With an increased understanding of the prevalence of low bone mass and its consequences as well an understanding of how to identify these patients and appropriately intervene, we can decrease the rates of adverse health outcomes related to low bone mass. While the focus of this review is on the impact of low bone density on bone health, it is important to recognize that other factors such as medical comorbidities, medications, tobacco use, a patient's fall risk, and overall nutritional status play a crucial role in a patient's overall bone health.⁹ With an array of successful treatment strategies available, it is crucial to identify patients who require low bone mass treatment. Ultimately, the imaging modalities and clinical assessment routinely used to diagnosis spinal disease are rich in information related to bone health. Spine care providers must learn to look beyond the spinal disease and detect and respond to the coexistent diminished bone quality.

Conclusions

This will increase the overall impact we have on our patient's spinal and general health.



Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Bayard C. Carlson, MD  <https://orcid.org/0000-0001-7854-0785>
Brett A. Freedman, MD  <https://orcid.org/0000-0002-3408-0163>

References

1. Wright NC, Looker AC, Saag KG, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. *J Bone Miner Res.* 2014;29(11):2520-2526.
2. Nicole C, Wright P. Osteoporosis Prevalence: Bone and Joint Decade. 2014. <http://www.boneandjointburden.org/2013-report/v-osteoporosis-and-bone-health/v>.
3. Bjerke BT, Zarrabian M, Aleem IS, et al. Incidence of osteoporosis-related complications following posterior lumbar fusion. *Global Spine J.* 2018;8(6):563-569.
4. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. *J Bone Miner Res.* 2007;22(3):465-475.
5. Demir T, Camuscu N, Tureyen K. Design and biomechanical testing of pedicle screw for osteoporotic incidents. *Proc Inst Mech Eng H.* 2012;226(3):256-262.
6. Kerezoudis P, Rinaldo L, Drazin D, et al. Association between vitamin D deficiency and outcomes following spinal fusion surgery: a systematic review. *World Neurosurg.* 2016;95:71-76.
7. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. *Osteoporos Int.* 2005;16(Suppl 2):S3-S7.
8. Camacho PM, Petak SM, Binkley N, et al. American association of clinical endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2016. *Endocr Pract.* 2016;22(Suppl 4):1-42.
9. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. *Osteoporos Int.* 2014;25(10):2359-2381.
10. Singer A, Exuzides A, Spangler L, et al. Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. *Mayo Clin Proc.* 2015;90(1):53-62.
11. Watkins-Castillo SI, Wright N. Prevalence of fragility fractures. 2014. <http://www.boneandjointburden.org/2014-report/vb1/prevalence-fragility-fractures>.
12. Roux C, Fechtenbaum J, Kolta S, Briot K, Girard M. Mild prevalent and incident vertebral fractures are risk factors for new fractures. *Osteoporos Int.* 2007;18(12):1617-1624.
13. Schousboe JT. Epidemiology of vertebral fractures. *J Clin Densitom.* 2016;19(1):8-22.
14. Tosteson AN, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ. Impact of hip and vertebral fractures on quality-adjusted life years. *Osteoporos Int.* 2001;12(12):1042-1049.
15. Lau JC, Ho KW, Sadiq S. Patient characteristics and risk of subsequent contralateral hip fracture after surgical management of first fracture. *Injury.* 2014;45(10):1620-1623.
16. Tajeu GS, Delzell E, Smith W, et al. Death, debility, and destitution following hip fracture. *J Gerontol A Biol Sci Med Sci.* 2014;69(3):346-353.
17. Svensson HK, Olofsson EH, Karlsson J, Hansson T, Olsson LE. A painful, never ending story: older women's experiences of living with an osteoporotic vertebral compression fracture. *Osteoporos Int.* 2016;27(5):1729-1736.
18. Hodsmen AB, Leslie WD, Tsang JF, Gamble GD. 10-year probability of recurrent fractures following wrist and other osteoporotic fractures in a large clinical cohort: an analysis from the Manitoba Bone Density Program. *Arch Intern Med.* 2008;168(20):2261-2267.
19. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. *Bone.* 2004;35(2):375-382.
20. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. *JAMA.* 2001;285(3):320-323.
21. Office of the Surgeon General (US). *Bone Health and Osteoporosis: A Report of the Surgeon General.* Rockville, MD: Office of the Surgeon General (US);2004.
22. Chen AT, Cohen DB, Skolasky RL. Impact of nonoperative treatment, vertebroplasty, and kyphoplasty on survival and morbidity after vertebral compression fracture in the Medicare population. *J Bone Joint Surg Am.* 2013;95(19):1729-1736.
23. Klazen CA, Lohle PN, de Vries J, et al. Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial. *Lancet.* 2010;376(9746):1085-1092.
24. Korovessis P, Vardakastanis K, Repantis T, Vitsas V. Balloon kyphoplasty versus KIVA vertebral augmentation—comparison of 2 techniques for osteoporotic vertebral body fractures: a prospective randomized study. *Spine.* 2013;38(4):292-299.
25. Nieuwenhuijse MJ, van Erkel AR, Dijkstra PD. Percutaneous vertebroplasty for subacute and chronic painful osteoporotic vertebral compression fractures can safely be undertaken in the first year after the onset of symptoms. *J Bone Joint Surg Br.* 2012;94(6):815-820.
26. Anderson PA, Froysheter AB, Tontz WL Jr. Meta-analysis of vertebral augmentation compared with conservative treatment for osteoporotic spinal fractures. *J Bone Miner Res.* 2013;28(2):372-382.
27. Freedman BA, Potter BK, Nesti LJ, Cho T, Kuklo TR. Missed opportunities in patients with osteoporosis and distal radius fractures. *Clin Orthop Relat Res.* 2007;454:202-206.
28. Freedman BA, Potter BK, Nesti LJ, Giuliani JR, Hampton C, Kuklo TR. Osteoporosis and vertebral compression fractures—continued missed opportunities. *Spine J.* 2008;8(5):756-762.
29. Prasad N, Sunderamoorthy D, Martin J, Murray JM. Secondary prevention of fragility fractures: are we following the guidelines? Closing the audit loop. *Ann R Coll Surg Engl.* 2006;88(5):470-474.
30. Bawa HS, Weick J, Dirschl DR. Anti-osteoporotic therapy after fragility fracture lowers rate of subsequent fracture: analysis of a large population sample. *J Bone Joint Surg Am.* 2015;97(19):1555-1562.
31. Hawley S, Leal J, Delmestri A, et al. Anti-osteoporosis medication prescriptions and incidence of subsequent fracture among primary hip fracture patients in England and Wales: an interrupted time-series analysis. *J Bone Miner Res.* 2016;31(11):2008-2015.

32. American Orthopaedic Association. Leadership in orthopaedics: taking a stand to own the bone. American Orthopaedic Association position paper. *J Bone Joint Surg Am.* 2005;87(6):1389-1391.
33. Bunta AD, Edwards BJ, Macaulay WB, et al. Own the bone, a system-based intervention, improves osteoporosis care after fragility fractures. *J Bone Joint Surg Am.* 2016;98(24):e109.
34. Tosi LL, Gliklich R, Kannan K, Koval KJ. The American Orthopaedic Association's "own the bone" initiative to prevent secondary fractures. *J Bone Joint Surg Am.* 2008;90(1):163-173.
35. Dirschl DR, Rustom H. Practice patterns and performance in U.S. fracture liaison programs: an analysis of >32,000 patients from the own the bone program. *J Bone Joint Surg Am.* 2018;100(8):680-685.
36. Formby PM, Kang DG, Helgeson MD, Wagner SC. Clinical and radiographic outcomes of transforaminal lumbar interbody fusion in patients with osteoporosis. *Global Spine J.* 2016;6(7):660-664.
37. Kim TH, Lee BH, Lee HM, et al. Prevalence of vitamin D deficiency in patients with lumbar spinal stenosis and its relationship with pain. *Pain Physician.* 2013;16(2):165-176.
38. Ravindra VM, Godzik J, Dailey AT, et al. Vitamin D levels and 1-year fusion outcomes in elective spine surgery: a prospective observational study. *Spine.* 2015;40(19):1536-1541.
39. Ravindra VM, Godzik J, Guan J, et al. Prevalence of vitamin D deficiency in patients undergoing elective spine surgery: a cross-sectional analysis. *World Neurosurg.* 2015;83(6):1114-1119.
40. Stoker GE, Buchowski JM, Bridwell KH, et al. Preoperative vitamin D status of adults undergoing surgical spinal fusion. *Spine.* 2013;38(6):507-515.
41. Inceoglu S, Ferrara L, McLain RF. Pedicle screw fixation strength: pullout versus insertional torque. *Spine J.* 2004;4(5):513-518.
42. Mehta H, Santos E, Ledonio C, et al. Biomechanical analysis of pedicle screw thread differential design in an osteoporotic cadaver model. *Clin Biomech.* 2012;27(3):234-240.
43. Bredow J, Boese CK, Werner CM, et al. Predictive validity of preoperative CT scans and the risk of pedicle screw loosening in spinal surgery. *Arch Orthop Trauma Surg.* 2016;136(8):1063-1067.
44. Sakai Y, Takenaka S, Matsuo Y, et al. Hounsfield unit of screw trajectory as a predictor of pedicle screw loosening after single level lumbar interbody fusion. *J Orthop Sci.* 2018;23(5):734-738.
45. Bernstein DN, Kurucan E, Menga EN, et al. Comparison of adult spinal deformity patients with and without rheumatoid arthritis undergoing primary non-cervical spinal fusion surgery: a nationwide analysis of 52,818 patients. *Spine J.* 2018;18(10):1861-1866.
46. Tempel ZJ, Gandhoke GS, Okonkwo DO, Kanter AS. Impaired bone mineral density as a predictor of graft subsidence following minimally invasive transposas lateral lumbar interbody fusion. *Eur Spine J.* 2015;24(Suppl 3):414-419.
47. Ruffoni D, Wirth AJ, Steiner JA, Parkinson IH, Müller R, van Lenthe GH. The different contributions of cortical and trabecular bone to implant anchorage in a human vertebra. *Bone.* 2012;50(3):733-738.
48. Varghese V, Saravana Kumar G, Krishnan V. Effect of various factors on pull out strength of pedicle screw in normal and osteoporotic cancellous bone models. *Med Eng Phys.* 2017;40:28-38.
49. Halvorson TL, Kelley LA, Thomas KA, Whitecloud TS, Cook SD. Effects of bone mineral density on pedicle screw fixation. *Spine.* 1994;19(21):2415-2420.
50. Cho JH, Hwang CJ, Kim H, Joo YS, Lee DH, Lee CS. Effect of osteoporosis on the clinical and radiological outcomes following one-level posterior lumbar interbody fusion. *J Orthop Sci.* 2018;23(6):870-877.
51. DeWald CJ, Stanley T. Instrumentation-related complications of multilevel fusions for adult spinal deformity patients over age 65: surgical considerations and treatment options in patients with poor bone quality. *Spine.* 2006;31(19 Suppl):S144-S151.
52. Yagi M, King AB, Boachie-Adjei O. Incidence, risk factors, and natural course of proximal junctional kyphosis: surgical outcomes review of adult idiopathic scoliosis. Minimum 5 years of follow-up. *Spine.* 2012;37(17):1479-1489.
53. Uei H, Tokuhashi Y, Maseda M, et al. Exploratory analysis of predictors of revision surgery for proximal junctional kyphosis or additional postoperative vertebral fracture following adult spinal deformity surgery in elderly patients: a retrospective cohort study. *J Orthop Surg Res.* 2018;13(1):252.
54. O'Leary PT, Bridwell KH, Lenke LGZ, et al. Risk factors and outcomes for catastrophic failures at the top of long pedicle screw constructs: a matched cohort analysis performed at a single center. *Spine.* 2009;34(20):2134-2139.
55. Kwon BK, Elgafy H, Keynan O, et al. Progressive junctional kyphosis at the caudal end of lumbar instrumented fusion: etiology, predictors, and treatment. *Spine.* 2006;31(17):1943-1951.
56. Meredith DS, Taher F, Cammisa FP Jr, Girardi FP. Incidence, diagnosis, and management of sacral fractures following multi-level spinal arthrodesis. *Spine J.* 2013;13(11):1464-1469.
57. Papadopoulos EC, Cammisa FP Jr, Girardi FP. Sacral fractures complicating thoracolumbar fusion of the sacrum. *Spine (Phila Pa 1976).* 2008;33(19):E699-707.
58. Puvanesarajah V, Shen FH, Cancienne JM, et al. Risk factors for revision surgery following primary adult spinal deformity surgery in patients 65 years and older. *J Neurosurg Spine.* 2016;25(4):486-493.
59. Sheu H, Liao JC, Lin YC. The fate of thoracolumbar surgeries in patients with Parkinson's disease, and analysis of risk factors for revision surgeries. *BMC Musculoskelet Disord.* 2019;20(1):106.
60. Vitamin D and Bone Health. Bone Basics. National Osteoporosis Foundation. 2013. <https://cdn.nof.org/wp-content/uploads/2016/02/Vitamin-D-and-Bone-Health.pdf>. Accessed October 28, 2018.
61. Kasperk C, Hillmeier J, Nöldge G, et al. Treatment of painful vertebral fractures by kyphoplasty in patients with primary osteoporosis: a prospective nonrandomized controlled study. *J Bone Miner Res.* 2005;20(4):604-612.
62. Sahota O, Masud T, San P, Hosking DJ. Vitamin D insufficiency increases bone turnover markers and enhances bone loss at the hip in patients with established vertebral osteoporosis. *Clin Endocrinol.* 1999;51(2):217-221.
63. Ohtori S, Orita S, Yamauchi K, et al. More than 6 months of teriparatide treatment was more effective for bone union than

- shorter treatment following lumbar posterolateral fusion surgery. *Asian Spine J.* 2015;9(4):573-580.
64. Inoue G, Ueno M, Nakazawa T, et al. Teriparatide increases the insertional torque of pedicle screws during fusion surgery in patients with postmenopausal osteoporosis. *J Neurosurg Spine.* 2014;21(3):425-431.
65. Lehman RA Jr, Dmitriev AE, Cardoso MJ, et al. Effect of teriparatide [rhPTH(1,34)] and calcitonin on intertransverse process fusion in a rabbit model. *Spine.* 2010;35(2):146-152.
66. O'Loughlin PF, Cunningham ME, Bukata SV, et al. Parathyroid hormone (1-34) augments spinal fusion, fusion mass volume, and fusion mass quality in a rabbit spinal fusion model. *Spine.* 2009;34(2):121-130.
67. Lehman RA Jr, Kuklo TR, Freedman BA, Cowart JR, Mense MG, Riew KD. The effect of alendronate sodium on spinal fusion: a rabbit model. *Spine J.* 2004;4(1):36-43.
68. Nagahama K, Kanayama M, Togawa D, Hashimoto T, Minami A. Does alendronate disturb the healing process of posterior lumbar interbody fusion? A prospective randomized trial. *J Neurosurg Spine.* 2011;14(4):500-507.
69. Pennes DR. T-score determination in bone densitometry. *AJR Am J Roentgenol.* 2011;197(6):W1166-W1167.